Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.
|Articles|January 15, 2003
- BioPharm International-01-01-2003
- Volume 16
- Issue 1
Rethinking the Economics of Chromatography: New Technologies and Hidden Costs
Author(s)Tim N. Warner, Sam Nuchumson
by Tim N. Warner and Sam Nuchumson, Pall Life Sciences If the hidden expenses associated with laboratory purchases ? labor, cleaning, buffers, validation, time delays ? are identified, reduced processing costs, higher throughput, and accelerated time-to-market are possible. This comparison between resin and membrane chromatography helps shed light on some hidden costs.
Advertisement
Articles in this issue
over 23 years ago
Biotech World: Canada's Supreme Court says "No" to Harvard Mouseover 23 years ago
Guest Editorial: At the Governance Crossroadover 23 years ago
Reducing Costs by Facility Designover 23 years ago
Survival Strategies: Board Compensation Changing with the TimesAdvertisement
Related to this article
Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.
Patients suffered pyrogenic reactions before Fresenius Kabi recalled 3 contaminated batches at its 430,000-sq-ft Melrose Park, Ill., biologics plant.
Sanofi is paying Regeneron up to $8 billion to co-develop REGN20423 and 3 other long-acting antibodies beyond dupilumab (Dupixent).
Real-world data show weight loss after switching to the Wegovy pill, Lilly reports positive hand and foot atopic dermatitis data, and Teva wins FDA approval for a Xgeva biosimilar.
In the OCTANE real-world analysis presented at EASD 2026, adults who switched from injectable semaglutide or tirzepatide to once-daily oral semaglutide lost an average of 4.1% of body weight after 3 months.
Denosumab-adet now covers all 3 Xgeva indications, widening lower-cost treatment access for cancer patients with bone complications.
More than half of patients achieved clear or almost clear hands and feet with lebrikizumab by week 16, and 77% reported satisfaction with clearance.
Advertisement
Advertisement